For many years, the SMITh team has been devoted to the development of drug candidates and pharmacological tools, mainly in the field of cancer. The drug candidates are either small molecules (ALDH inhibitors) or antibody drug conjugates (ADC) using innovative technologies developped by SMITh team and partners. The pharmacological tools concern RNA binders (homocarbonyltopsentin - PK4C9 with application in spinal muscular atrophy), kinase inhibitors (finisterin and meriolin series as potent anticancer drugs) and transglutaminase inhibitors (BJJF078).